A version of this post written by my colleague Amy O'Connor originally appeared on LillyPad US.
Every year, the BIO International Convention brings together the foremost minds in the biotechnology field to discuss the state of the industry and how to accelerate the innovation that improves lives around the world. It's been a great (and humid) first few days at this year's convention in Philadelphia with plenty of insights to share already.
Each time I go to BIO, it seems another theme takes center stage. A couple years ago everyone was talking about "big data" and the digitization of health; last year, intellectual property and trade were hot topics. This year, the first couple days of events have taken a decidedly patient-centered approach. Over the course of today's panels and breakouts, it became clear that companies aren't just talking the talk, they're ready to walk the walk. Advocacy groups, including the Pancreatic Cancer Action Network, the ALS Association, the National Health Council, the Alliance for Aging Research, and many others in the audience, joined the conversation to share their ideas on how we can create a more consistent, predictable approach to bring the patient voice to medical discovery, regulatory decisions, the value discussion, and policy decisions.
The takeaway? Companies, regulators, and payors have demonstrated a true desire to hear from patients, but collecting and interpreting that data in a systematic way still remains a challenge. With continued conversations on the Hill about the 21st Century Cures Act and negotiations for PDUFA VI coming up quickly, it’s clear that we need all stakeholders to come together to pave the way forward for truly patient-focused drug development.
Check out the Storify below for highlights from the conversation today and be sure to follow @LillyPad for more news from the BIO front lines. See you at #BIO2015!